Phio Pharmaceuticals(PHIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PHIO Phio Pharmaceuticals

盘后交易 03-09 17:11:01 EDT

1.21

+0.05

+4.31%

盘后1.20

-0.01-0.83%

17:02 EDT

最高1.25	最低1.14	成交量38.02万
今开1.15	昨收1.16	日振幅9.48%
总市值1,406万	流通市值1,397万	总股本1,162万
成交额45.18万	换手率3.29%	流通股本1,155万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PHIO","market":"US","secType":"STK","nameCN":"Phio Pharmaceuticals","latestPrice":1.21,"timestamp":1773086400000,"preClose":1.16,"halted":0,"volume":380196,"hourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.21,"latestTime":"17:02 EDT","volume":17009,"amount":20447.973169499997,"timestamp":1773090122439,"change":-0.01,"changeRate":-0.008264,"amplitude":0.020661},"delay":0,"changeRate":0.043103448275862113,"floatShares":11548100,"shares":11617300,"eps":-1.453538,"marketStatus":"盘后交易","change":0.05,"latestTime":"03-09 17:11:01 EDT","open":1.15,"high":1.25,"low":1.14,"amount":451848.8407284,"amplitude":0.094828,"askPrice":1.22,"askSize":1568,"bidPrice":1.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.453538,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1773100800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.16,"preHourTrading":{"tag":"盘前","latestPrice":1.16,"preClose":1.16,"latestTime":"09:27 EDT","volume":4565,"amount":5368.9097385000005,"timestamp":1773062874152,"change":0,"changeRate":0,"amplitude":0.017241},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.21,"latestTime":"17:02 EDT","volume":17009,"amount":20447.973169499997,"timestamp":1773090122439,"change":-0.01,"changeRate":-0.008264,"amplitude":0.020661},"volumeRatio":0.644376,"impliedVol":2.2612,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/PHIO","defaultTab":"news","newsList":[{"id":"1102312799","title":"Phio制药最终队列最高剂量浓度实现85%病理缓解率（7例患者中6例显效）","url":"https://stock-news.laohu8.com/highlight/detail?id=1102312799","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102312799?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:39","pubTimestamp":1770727152,"startTime":"0","endTime":"0","summary":"Phio制药在其临床试验最终队列研究中取得突破性进展——当使用最高剂量浓度时，病理缓解率高达85%。该数据来源于7例参与试验的患者群体，其中6例表现出显著治疗效果。这一结果不仅验证了剂量递增策略的有效性，更为后续临床开发路径提供了关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"1112723006","title":"Phio制药公司：所有5个剂量递增队列均未发现严重不良事件或毒性反应——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1112723006","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112723006?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:37","pubTimestamp":1770727051,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件，Phio Pharmaceuticals Corp（简称：Phio Pharmaceuticals）在其临床试验中取得积极进展。文件显示，在所有5个剂量递增队列中，均未观察到任何严重不良事件或毒性反应。\n这一结果标志着公司在药物安全性方面迈出重要一步，为后续临床开发奠定坚实基础。研究数据的稳健性进一步验证了其候选疗法的潜在耐受性。\n分析指出，无严重安全性问题的发现，有望加速Phio Pharmaceuticals推进相关治疗方案的研发进程，并为投资者带来信心支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2609630602","title":"Phio Pharmaceuticals Corp.盘中异动 急速下跌5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609630602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609630602?lang=zh_cn&edition=full","pubTime":"2026-02-04 23:33","pubTimestamp":1770219224,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日23时33分，Phio Pharmaceuticals Corp.股票出现波动，股价急速下跌5.27%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.75%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020423334597a4e343&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020423334597a4e343&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2601396103","title":"Phio Pharmaceuticals Corp.盘中异动 下午盘快速拉升6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601396103","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601396103?lang=zh_cn&edition=full","pubTime":"2026-01-08 03:52","pubTimestamp":1767815556,"startTime":"0","endTime":"0","summary":"北京时间2026年01月08日03时52分，Phio Pharmaceuticals Corp.股票出现异动，股价快速拉升6.09%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为2.28%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010803523797a135a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010803523797a135a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2593443084","title":"Phio Pharmaceuticals Corp.盘中异动 大幅下跌5.45%报1.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593443084","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593443084?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:33","pubTimestamp":1766500433,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日22时33分，Phio Pharmaceuticals Corp.股票出现波动，股价大幅跳水5.45%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体跌幅为0.13%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Genenta Science Spa、Neurosense Therapeutics Ltd.涨幅较大，Lexaria Bioscience Corp.、Pmgc Holdings Inc.、Reviva Pharmaceuticals Holdings, Inc.较为活跃，换手率分别为61.95%、17.90%、15.79%，振幅较大的相关个股有Chemomab Therapeutics Ltd、健永生技、Radiopharm Theranostics Limited，振幅分别为15.46%、13.73%、10.88%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223353a46f5a44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223353a46f5a44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"1182020903","title":"Phio Pharmaceuticals Corp - Ph-762在所有入组患者的每个增量剂量组中均表现良好耐受","url":"https://stock-news.laohu8.com/highlight/detail?id=1182020903","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182020903?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:57","pubTimestamp":1766498237,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp - Ph-762在所有入组患者的每个增量剂量组中均表现良好耐受","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"1181711469","title":"Phio Pharmaceuticals - 持续推进2026年可商业化药品的交付","url":"https://stock-news.laohu8.com/highlight/detail?id=1181711469","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181711469?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:56","pubTimestamp":1766498178,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals - 持续推进2026年可商业化药品的交付","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"1165251729","title":"Phio Pharmaceuticals Corp 提交证券交易委员会申请，拟向出售股东增发至多1180万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1165251729","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165251729?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:09","pubTimestamp":1763672950,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp 提交证券交易委员会申请，拟向出售股东增发至多1180万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"1155175320","title":"Phio Pharmaceuticals Corp - 安全委员会对Intasyl Ph-762的最大剂量给予积极评估 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1155175320","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155175320?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:10","pubTimestamp":1762175410,"startTime":"0","endTime":"0","summary":"Phio Pharmaceuticals Corp - 安全委员会对Intasyl Ph-762的最大剂量给予积极评估 - SEC文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2517016534","title":"Phio Pharmaceuticals Corp.盘中异动 大幅下挫5.04%报1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517016534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517016534?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:30","pubTimestamp":1741271425,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时30分，Phio Pharmaceuticals Corp.股票出现异动，股价大幅下挫5.04%。截至发稿，该股报1.32美元/股，成交量2651股，换手率0.06%，振幅0.00%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.00%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223025abeb76f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223025abeb76f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2517941652","title":"Phio Pharmaceuticals Corp.盘中异动 急速上涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517941652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517941652?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:05","pubTimestamp":1741190746,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时05分，Phio Pharmaceuticals Corp.股票出现波动，股价大幅上涨5.23%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为1.31%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306000546abe9cdfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306000546abe9cdfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2516608031","title":"Phio Pharmaceuticals Corp.盘中异动 早盘急速下挫5.30%报1.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608031","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516608031?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:59","pubTimestamp":1741100396,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时59分，Phio Pharmaceuticals Corp.股票出现异动，股价快速下跌5.30%。截至发稿，该股报1.25美元/股，成交量3.962万股，换手率0.83%，振幅5.30%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.36%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225956a25f0d52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304225956a25f0d52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2516681006","title":"Phio Pharmaceuticals Corp.盘中异动 下午盘股价大跌7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516681006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516681006?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:19","pubTimestamp":1741033151,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时19分，Phio Pharmaceuticals Corp.股票出现异动，股价快速下跌7.75%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4599.47%、213.16%、183.18%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040419119637f9da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040419119637f9da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2514090074","title":"Phio Pharmaceuticals Corp.盘中异动 快速下挫6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090074?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:33","pubTimestamp":1740494014,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时33分，Phio Pharmaceuticals Corp.股票出现波动，股价大幅下挫6.01%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为759.92%、468.74%、242.26%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp、Dominari Holdings Inc.，振幅分别为20.51%、14.67%、11.73%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223334962ff2df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223334962ff2df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2513560773","title":"Phio Pharmaceuticals Corp.盘中异动 快速跳水5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513560773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513560773?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:37","pubTimestamp":1740411439,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时37分，Phio Pharmaceuticals Corp.股票出现波动，股价大幅下跌5.39%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为210.43%、89.48%、28.02%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242337209891056b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242337209891056b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2512911621","title":"Phio Pharmaceuticals Corp.盘中异动 快速下跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512911621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512911621?lang=zh_cn&edition=full","pubTime":"2025-02-19 04:25","pubTimestamp":1739910304,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日04时25分，Phio Pharmaceuticals Corp.股票出现波动，股价快速下跌5.52%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为0.61%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为912.66%、214.83%、173.12%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219042504a24af4eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219042504a24af4eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2511694823","title":"Phio Pharmaceuticals Corp.盘中异动 早盘大幅上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511694823","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511694823?lang=zh_cn&edition=full","pubTime":"2025-02-14 23:23","pubTimestamp":1739546607,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日23时23分，Phio Pharmaceuticals Corp.股票出现波动，股价急速上涨5.03%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体跌幅为0.11%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214232327abcf127a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214232327abcf127a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2510860846","title":"Phio Pharmaceuticals Corp.盘中异动 股价大跌5.77%报1.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510860846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510860846?lang=zh_cn&edition=full","pubTime":"2025-02-11 00:50","pubTimestamp":1739206214,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日00时50分，Phio Pharmaceuticals Corp.股票出现波动，股价大幅下跌5.77%。截至发稿，该股报1.78美元/股，成交量17.966万股，换手率3.76%，振幅5.82%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体跌幅为0.09%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110050149880930e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110050149880930e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0},{"id":"2509725908","title":"Phio Pharmaceuticals Corp.盘中异动 早盘股价大跌5.91%报1.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509725908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509725908?lang=zh_cn&edition=full","pubTime":"2025-02-08 00:12","pubTimestamp":1738944756,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日00时12分，Phio Pharmaceuticals Corp.股票出现异动，股价大幅跳水5.91%。截至发稿，该股报1.91美元/股，成交量9.5565万股，换手率2.00%，振幅6.16%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体跌幅为0.29%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208001236987dbff0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208001236987dbff0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PHIO"],"gpt_icon":0},{"id":"2509328004","title":"Phio Pharmaceuticals Corp.盘中异动 股价大跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509328004","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509328004?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:17","pubTimestamp":1738768664,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时17分，Phio Pharmaceuticals Corp.股票出现异动，股价快速下挫5.39%。Phio Pharmaceuticals Corp.股票所在的生物技术行业中，整体涨幅为1.19%。其相关个股中，Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大，Pasithea Therapeutics Corp.、Oragenics Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为3901.96%、1141.21%、671.41%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028，振幅分别为86.20%、59.80%、54.05%。Phio Pharmaceuticals Corp.公司简介：Phio Pharmaceuticals Corp是一家临床阶段的生物技术公司，其专有的 INTASYL 自传递 RNAi 技术平台旨在使免疫细胞更有效地杀死肿瘤细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205231744abc387e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205231744abc387e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PHIO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phiopharma.com","stockEarnings":[{"period":"1week","weight":0.0175},{"period":"1month","weight":0.2541},{"period":"3month","weight":-0.1145},{"period":"6month","weight":-0.4314},{"period":"1year","weight":-0.1343},{"period":"ytd","weight":0.1048}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Phio Pharmaceuticals Corp.于2011年9月8日在特拉华州注册成立。Phio是一家临床阶段的生物制药公司，利用其专有的INTASYL小干扰RNA基因沉默技术，增强免疫细胞靶向和摧毁肿瘤细胞的效力。公司致力于开发利用INTASYL技术特异性靶向抑制人体抗癌能力的蛋白质的疗法，无需依赖特殊制剂或药物递送系统。Phio Pharmaceuticals致力于发现和开发创新癌症疗法，旨在开辟通往无癌未来的新途径，公司采用单一运营部门和单一报告部门的模式。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.043064},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.04268},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.073339},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.07123},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.031751},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004305},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.093442},{"month":8,"riseRate":0.25,"avgChangeRate":-0.042027},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.099086},{"month":10,"riseRate":0.25,"avgChangeRate":-0.134645},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.090172},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.146601}],"exchange":"NASDAQ","name":"Phio Pharmaceuticals","nameEN":"Phio Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phio Pharmaceuticals(PHIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Phio Pharmaceuticals(PHIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Phio Pharmaceuticals,PHIO,Phio Pharmaceuticals股票,Phio Pharmaceuticals股票老虎,Phio Pharmaceuticals股票老虎国际,Phio Pharmaceuticals行情,Phio Pharmaceuticals股票行情,Phio Pharmaceuticals股价,Phio Pharmaceuticals股市,Phio Pharmaceuticals股票价格,Phio Pharmaceuticals股票交易,Phio Pharmaceuticals股票购买,Phio Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phio Pharmaceuticals(PHIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Phio Pharmaceuticals(PHIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}